Lessons from trials in hypertensive type 2 diabetic patients

Area of Science:

• Cardiology
• Nephrology
• Endocrinology

Background:

• Type 2 diabetes (T2D) and hypertension significantly increase cardiovascular and renal risks.
• Blood pressure levels below traditional hypertension thresholds pose risks in T2D patients.
• Intensive blood pressure reduction is demonstrably beneficial in T2D.

Purpose of the Study:

• To review the evidence for intensive blood pressure lowering in T2D.
• To evaluate the efficacy of different antihypertensive drug classes.
• To assess the impact of blood pressure control on renal endpoints in T2D.

Main Methods:

• Systematic review of clinical trials and evidence.
• Analysis of cardiovascular and renal outcomes in T2D patients with hypertension.
• Comparison of different antihypertensive drug classes, including angiotensin II receptor antagonists (ARBs) and angiotensin-converting enzyme (ACE) inhibitors.

Main Results:

• Combination therapy is frequently necessary but achieving target blood pressure, especially systolic <130 mm Hg, remains challenging.
• ARBs show robust evidence for reducing renal endpoints in T2D compared to ACE inhibitors.
• Losartan demonstrated cardiovascular benefits over atenolol, but irbesartan did not show superiority over amlodipine.
• Strict blood pressure control aids in preventing microalbuminuria, but may not guarantee glomerular filtration rate preservation.

Conclusions:

• Intensive blood pressure management is essential for T2D patients to mitigate cardiovascular and renal complications.
• Angiotensin II receptor antagonists offer significant renal protection in T2D.
• Further research is needed to clarify optimal drug strategies for achieving blood pressure goals and preserving renal function in this population.